Factors associated with leakage after reversal of protective stoma in patients with locally advanced rectal cancer following curative resection and anastomosis
European Journal of Surgical Oncology · 2025
DOI: 10.1016/j.ejso.2024.108698 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Surgical Oncology, 2025. Verfasst von Miao-Ling Tsai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Department of Surgery, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan. Hauptthemen laut MEDLINE: Anastomotic Leak, Rectal Neoplasms, Ileostomy, Proctectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Anastomotic leakage (AL) is a significant complication in colorectal surgery with numerous general and specific risk factors. The determinants of colorectal AL following the reversal of a protective defunctioning ileostomy remain unclear and warrant further investigation. MATERIAL AND METHODS: Data from April 2008 to December 2014 were collected and retrospectively reviewed for 361 consecutive patients who underwent protective ileostomy reversal following curative resection with anastomosis for rectal cancer. The baseline, treatment, and oncological variables of patients associated with post-reversal AL were evaluated using univariate and multivariate logistic regression analysis. The impact of AL on long-term survival outcomes was assessed using Kaplan-Meier survival analyses. RESULTS: In a study of 361 patients, 52 (14.4 %) experienced leakage following stoma reversal, manifesting at a median of 5.7 months. Multivariable logistic regression analysis revealed that an anastomosis located less than 7 cm from the anal verge (OR 2.82, p = 0.008), a side-to-end anastomotic configuration (OR 2.02, p = 0.036), involvement of the circumferential resection margin (OR 6.46, p = 0.043), and adjuvant radiotherapy (OR 4.69, p = 0.003) significantly predicted post-reversal AL. Notably, five-year overall survival (63.4 % vs. 90.3 %, p < 0.0001) and disease-free survival (46.9 % vs. 71.1 %, p = 0.001) were significantly lower in patients with post-reversal AL. CONCLUSIONS: Our analysis identified several clinicopathological factors associated with post-reversal AL, which is linked to a significant decrease in long-term survival and oncological outcomes. Alleviating these adverse effects necessitates ensuring early detection and effective management of leaks among high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of General Surgery, Department of Surgery, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.
- Division of Colorectal Surgery, Department of Surgery, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
- Division of Colorectal Surgery, Department of Surgery, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan; Department of Surgery, National Taiwan University Cancer Center, Taiwan. Electronic add…
Zitieren
APA
Tsai, M. L., Hung, J. S., Huang, J., & Lin, B. R. (2025). Factors associated with leakage after reversal of protective stoma in patients with locally advanced rectal cancer following curative resection and anastomosis. European Journal of Surgical Oncology. https://doi.org/10.1016/j.ejso.2024.108698
Vancouver
Tsai ML, Hung JS, Huang J, Lin BR. Factors associated with leakage after reversal of protective stoma in patients with locally advanced rectal cancer following curative resection and anastomosis. European Journal of Surgical Oncology. 2025. doi:10.1016/j.ejso.2024.108698
BibTeX
@article{Tsai2025,
author = {Tsai, Miao-Ling and Hung, Ji-Shiang and Huang, John and Lin, Been-Ren},
title = {Factors associated with leakage after reversal of protective stoma in patients with locally advanced rectal cancer following curative resection and anastomosis},
journal = {European Journal of Surgical Oncology},
year = {2025},
doi = {10.1016/j.ejso.2024.108698}
}
EUVIMED